Britain’s largest pharmacy chain has come under scrutiny after reports that Boots has been dispensing cross-sex hormones to minors even as the NHS moves in the opposite direction, citing serious concerns about safety, evidence, and long-term harm. The Telegraph reported on April 4 that Boots was allowing the sale of these drugs to under-18s despite growing concern inside the health system over their effects on children. That report emerged just weeks after NHS England launched a consultation on removing masculinising and feminising hormones as a routine treatment for minors.
The policy backdrop is important. In December 2024, the UK government made the ban on puberty blockers for gender dysphoria in under-18s indefinite, with a future review scheduled for 2027. The move followed mounting concern over weak evidence and potential harms. In March 2026, NHS England went further, opening a consultation on whether cross-sex hormones should also cease to be routinely available for children and adolescents, saying there is insufficient evidence to show the drugs are safe or clinically effective enough for standard use in that age group.
That combination has exposed a growing contradiction in Britain’s gender-medicine debate. Public authorities are acknowledging that these are powerful interventions with uncertain long-term consequences, yet access routes outside ordinary NHS practice appear to remain available. Reporting tied to the Telegraph story indicates the concern is specifically that under-18s may still obtain cross-sex hormones through prescriptions being filled by major pharmacies, even while the NHS itself is stepping back from routine pediatric use.
The Cass Review has already reshaped this field by urging far greater caution, and the government’s puberty-blocker restrictions reflected that shift. Now the same scrutiny is falling on cross-sex hormones, with critics asking why commercial dispensing appears to be outpacing official medical restraint.
The real scandal is not that Britain is becoming more cautious. It is that the caution came so late. If the NHS now says the evidence is too weak to justify routine hormone treatment for minors, then every institution still facilitating that pipeline deserves serious public scrutiny.